CClinicalTrials.gg
Status unknownNCT00813475Updated Dec 23, 2008

Effect of Diabetes Control on Outcome in Hospitalized Patients: A National Israeli Study

An interventional study of Basal bolus insulin regimen (tight glucose control) and Basal bolus insulin regimen (standard control) in Diabetes, sponsored by Assaf-Harofeh Medical Center. Status unknown at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-12-23.

Sponsored by Assaf-Harofeh Medical Center · Not applicable, Interventional, and Health services research

The sponsor has not verified this record recently (last verified Dec 2008), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To test whether tight glucose control is associated with better clinical outcome compared to less-tight control, among diabetic patients hospitalized in internal medicine wards.

Read the detailed description

Patient characteristics:

Patients admitted to internal medicine departments in public hospitals of Israel who have pre-admission diagnosis of diabetes, or have a random plasma glucose >200 mg/dl on admission

Eligibility criteria

  1. Age: >18 years
  2. Fasting plasma glucose > 140 mg/dl or non-fasting plasma glucose >200 mg/dl in two separate blood tests if non-diabetic, or in a single blood test if have pre-diagnosed diabetes
  3. Able to understand the study objective and methods and willing to provide a written informed consent
  4. No significant liver disease
  5. Serum creatinine \<2.0 mg/dl

Exclusion criteria

  1. Significant cognitive impairment
  2. History of hypoglycemia unawareness or clinical autonomic diabetic neuropathy
  3. Known allergy to insulin analogues
  4. Diabetic ketoacidosis or non-ketotic hyperosmolar coma on admission

Process of patient recruitment and randomization:

  1. Enrolment of eligible patients signing the informed consent.
  2. Assignment of patients to different treatment arms according to randomization scheme provided by the central organizing committee.
  3. The ratio of patients' assignment to the active or to the control study arm will be 1:1 for each participating ward.

Protocol:

Basal bolus insulin treatment will be applied to achieve tight glucose target (mean fasting blood glucose\<130 mg/dl and not above 180 mg/dl during the day) compared to patients treated to achieve less tight glucose targets (mean fasting blood glucose\<200 mg/dl and not above 220 mg/dl during the day)will influence cardiovascular and general clinical outcome.

Primary outcome: All-cause mortality (including in-hospital and up to 12 months post discharge) or re-admission to hospital

Secondary outcomes:

Total number of in-hospital days during one year follow-up (including the index hospital admission)

The rate of any major clinical events (all-cause mortality, hospital acquired infection, organ failure, need of ventilation support, need of vasoactive amine administration, need of central line insertion, hospital admission for stroke, acute coronary event, severe bacterial or fungal infection) during one year follow-up

Hypoglycemic events during index hospital stay.

02

Conditions studied

  • Diabetes

Keywords

  • cardio vascular outcome
03

In context

Lead sponsor

Assaf-Harofeh Medical Center is the lead sponsor of 258 studies on the registry; 40 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Age: >18 years
  2. Fasting plasma glucose > 140 mg/dl or non-fasting plasma glucose >200 mg/dl in two separate blood tests if non-diabetic, or in a single blood test if have pre-diagnosed diabetes
  3. Able to understand the study objective and methods and willing to provide a written informed consent
  4. No significant liver disease
  5. Serum creatinine \<2.0 mg/dl

Exclusion criteria

-

Exclusion Criteria:

  1. Significant cognitive impairment
  2. History of hypoglycemia unawareness or clinical autonomic diabetic neuropathy
  3. Known allergy to insulin analogues
  4. Diabetic ketoacidosis or non-ketotic hyperosmolar coma on admission

    -

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    tight control

    Drug: Basal bolus insulin regimen (tight glucose control)

  • Experimental
    standard control

    basal bolus insulin regimen

    Drug: Basal bolus insulin regimen (standard control)

Interventions

  • DrugBasal bolus insulin regimen (tight glucose control)

    Basal bolus insulin regimen

  • DrugBasal bolus insulin regimen (standard control)

    basal bolus insulin regimen

06

What researchers measure

Primary outcomes

  1. All-cause mortality (including in-hospital and up to 12 months post discharge) or re-admission to hospital

    Time frame: 1.5 years

Secondary outcomes

  1. Total # of in-hospital days during 1 year follow-up.The rate of any major clinical events during 1 year follow-up. Hypoglycemic events during index hospital stay

    Time frame: 1.5

07

Study locations

1 site
  • Assaf Harofeh Medical Center
    Zerifin, 70300, Israel
    • Andreas E Buchs, MD · Principal investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 23, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00813475
Lead sponsor
Assaf-Harofeh Medical Center
First posted
Dec 23, 2008
Start date
Jan 2009
Primary completion
Jun 2011 (estimated)
Completion
Jul 2011 (estimated)
Last update
Dec 23, 2008

Study contacts

Andreas E Buchs, MD
Contact
abuchs@asaf.health.gov.il
972-57-7345025

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion